| REVIEW ARTICLE |
|
| Year : 2010 | Volume
: 11
| Issue : 1 | Page : 10-15 |
|
|
Natriuretic peptide system and cardiovascular disease
Federico Cacciapuoti
Associate Professor of Internal Medicine, Second University of Naples, Italy
Correspondence Address:
Federico Cacciapuoti
Cattedra di Medicina Interna, Facoltą di Medicina e Chirurgia, Seconda, Universitą di Napoli, Piazza L. Miraglia 2,Napoli-80138
Italy
 Source of Support: None, Conflict of Interest: None  | Check |
PMID: 21042458 
|
|
|
The mammalian Natriuretic Peptide (NP) system consists of neuro-hormones, such as atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), c-type natriuretic peptide (CNP), and the N-Terminal fragment of BNP (NT-pro-BNP). In response to some cardiovascular derangement the heart (acting as an endocrine organ), brain and other structures secretes natriuretic peptides in an attempt to restore normal circulatory conditions. Their actions are modulated through membrane-bound guanylyl cyclased (GC) receptors. They induce diuresis, natriuresis and vasodilation in the presence of congestive heart failure. These neuro-hormones also play a role in the suppression of neointimal formation after vascular injury. In addition, they act as antifibrotic and antihypertrophic agents preventing cardiac remodeling after myocardial infarction. Further, NP have diagnostic and prognostic role in heart failure, vasoconstriction, left ventricular late remodeling after MI and others. At present, some drugs such as Nesiritide, NEP inhibitors and vasopeptidase inhibitors were synthetized from NP, to antagonize these cardiovascular derengements. In future, it will be possibile to elaborate some drugs similar to petidase inhibitors and some CNP-like drugs able to reduce many symptoms of cardiovascular derangements without significant side effects. |
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
